Elevation Oncology Inc (ELEV)

NASDAQ
1.33
+0.05(+3.91%)
  • Volume:
    54,568
  • Day's Range:
    1.29 - 1.35
  • 52 wk Range:
    1.12 - 13.39

ELEV Overview

Prev. Close
1.28
Day's Range
1.29-1.35
Revenue
-
Open
1.32
52 wk Range
1.12-13.39
EPS
-2.54
Volume
54,568
Market Cap
30.99M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
652,579
P/E Ratio
-0.524
Beta
1.07
1-Year Change
-85.54%
Shares Outstanding
23,300,896
Next Earnings Date
Nov 11, 2022
What is your sentiment on Elevation Oncology?
or
Vote to see community's results!

Elevation Oncology Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Elevation Oncology Inc Company Profile

Elevation Oncology Inc Company Profile

Employees
23

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company’s lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellSell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell